Allergy Therapeutics plc (AIM: AGY), a UK based biotechnology company that specialises in allergy vaccines, on Wednesday announced positive outcomes from the G306 Phase III trial of Grass MATA MPL, its subcutaneous allergen-specific immunotherapy (SCIT) for allergic rhinoconjunctivitis due to grass pollen.

According to Allergy Therapeutics, the active treatment group achieved a highly significant reduction in Combined Symptom & Medication Score (CSMS) (p≤0.0024) over the peak pollen season, leading to study success without the need for a second season cohort.

The company is compiling a comprehensive dataset, including primary and secondary endpoints, for regulatory discussions on the marketing authorisation application. Anticipated scientific advice meetings with health authorities in late Q1 2024 will outline the pathway for progression.

Grass MATA MPL, designed as a pre-seasonal subcutaneous immunotherapy product, addresses allergic rhinitis and/or rhinoconjunctivitis. The product contains a modified allergoid extract of 13 grass pollens adsorbed to L-tyrosine as a depot adjuvant system formulation. Monophosphoryl lipid-A (MPL) serves as an adjuvant to enhance the immunogenic effect and promote a helper T-cell Type 1 (Th1) immune response.

Allergic rhinitis and rhinoconjunctivitis, caused by common aeroallergens, represent the target conditions for Grass MATA MPL. Seasonal allergic rhinitis, associated with tree, grass or weed pollen and perennial allergic rhinitis, linked to dust mite residue, mold spores or animal dander, are the focus of the company's therapeutic interventions.

Allergy Therapeutics markets products in nine European countries and through distribution agreements in ten additional countries. Its clinical development pipeline includes vaccines for grass, tree, house dust mite and peanut allergies.